Abstract
Purpose: To conduct a pilot study of pegylated interferon alpha 2b (PEGIFNα2b) for treatment of ocular surface squamous neoplasia (OSSN). Methods: Three patients with histologically proven OSSN were studied prospectively. Patients were given subconjunctival/perilesional injections of 1μg/kg of PEGIFNα2b (PEG Intron, Schering-Plough, Kenilworth, NJ) until the tumor resolved. Patients were followed clinically and photographically for evidence of tumor resolution and recurrence. Results: All patients had clinical resolution of the tumor. The mean time to resolution was 47 days. During the follow-up time after resolution of the lesion (mean 41 months), one patient had disease recurrence 7 months after clinical resolution. This was successfully treated with one further injection. Conclusion: PEGIFNα2b may be a viable medical alternative for the treatment of OSSN. Future studies will be needed to evaluate whether PEGIFNα2b is as effective as recombinant interferon alpha 2b.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 254-260 |
| Number of pages | 7 |
| Journal | Ocular Immunology and Inflammation |
| Volume | 18 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 2010 |
Keywords
- Conjunctival intraepithelial neoplasia
- Ocular surface squamous neoplasia
- Pegylated interferon
ASJC Scopus subject areas
- Ophthalmology
- Immunology and Allergy